西布曲明对比奥利司他治疗肥胖症的Meta分析

中国临床药理学与治疗学 ›› 2010, Vol. 15 ›› Issue (6): 651-656.

西布曲明对比奥利司他治疗肥胖症的Meta分析

田宏亮^1,2, 葛赛^1,3, 袁浩^1,3, 唐震², 张丽菡², 田金徽¹, 杨克虎^1,3

¹兰州大学基础医学院循证医学中心, ²第二临床医学院, ³第一临床医学院,兰州 730000,甘肃

收稿日期:2010-02-25 修回日期:2010-06-03 出版日期:2010-06-26 发布日期:2020-09-16
通讯作者: 田金徽,男,医学博士在读,讲师,主要从事循证医学研究。 Tel:13619342312 E-mail:tjh996@163.com
作者简介:田宏亮,男,本科在读,主要从事循证医学研究。Tel:13919838005 E-mail:tiankunpeng@126.com
基金资助:
国家大学生创新性实验计划(091073061)

Sibutramine versus orlistat for obesity: A Meta-analysis of randomized controlled trials

TIAN Hong-liang^1,2, GE Sai^1,3, YUAN Hao^1,3, TANG Zhen², ZHANG Li-han², TIAN Jing-hui¹, YANG Ke-hu^1,3

¹ Evidence Based Medicine Center, School of Basic Medical Sciences, Lanzhou University;
² the Second Clinical Medicine College of Lanzhou University;
³ the First Clinical Medicine College of Lanzhou University, Lanzhou 730000, Gansu, China

Received:2010-02-25 Revised:2010-06-03 Online:2010-06-26 Published:2020-09-16

摘要/Abstract

摘要： 目的: 系统评价西布曲明与奥利司他治疗肥胖症的临床疗效及其临床应用价值。方法: 计算机检索PubMed、EMBASE、SCI、Cochrane Library、中国生物医学文献数据库、中文科技期刊全文数据库、中国期刊全文数据库及中华医学会数字化期刊,收集西布曲明与奥利司他治疗肥胖症的随机对照试验,检索时间截至2009年12月。采用Cochrane系统评价员手册文献质量评价标准评价纳入研究质量,用RevMan 5.0软件进行Meta分析。结果: 共纳入5个随机对照试验,研究地点均在国外。Meta分析结果显示:在体重减轻、体重指数(BMI)降低、腰围减少、低密度脂蛋白降低的比较上,西布曲明组与奥利司他组均有明显的减肥效果,但两药减肥效果无差异。两组间不良反应较少,但由于药物作用机制不同,不良反应的表现不同。结论: 西布曲明与奥利司他在治疗肥胖上有显著疗效,两者间无明显差异,同时两组药物间不良反应表现不同。

关键词: 西布曲明, 奥利司他, 随机对照试验, Mata分析

Abstract: AIM: To compare the efficacy and investigate the clinic value between sibutramine and orlistat for obesity. METHODS: The database was retrieved from PubMed, EMBASE, SCI, the Cochrane Library, Chinese Biomedical Literature Database, China Journal Full Text Database, Chinese Medical Association Journals, and references of the included studies up to December 2009. Randomized control trials (RCT) of sibutramine versus orlistat for obesity were included. The quality of the included studies was evaluated by Handbook recommend standard. Data were analyzed by RevMan 5.0 from the Cochrane Collaboration. RESULTS: Five RCTs were included. Meta-analysis showed that there were no differences between sibutramine and orlistat for obesity in weight loss, body mass index(BMI) decrease, waist circumference decrease and LDL-C change. Although there were fewer adverse events in the two groups, the form of adverse events were different because of the different mechanism of two drugs. CONCLUSION: Sibutramine and Orlistat have significant effects in the treatment of obesity. Meanwhile, there is no significant difference between two drugs, while the performance of two groups of drug adverse events is different.

Key words: Sibutramine, Orlistat, Randomized controlled trial, Meta analysis

中图分类号:

R311

田宏亮, 葛赛, 袁浩, 唐震, 张丽菡, 田金徽, 杨克虎. 西布曲明对比奥利司他治疗肥胖症的Meta分析[J]. 中国临床药理学与治疗学, 2010, 15(6): 651-656.

TIAN Hong-liang, GE Sai, YUAN Hao, TANG Zhen, ZHANG Li-han, TIAN Jing-hui, YANG Ke-hu. Sibutramine versus orlistat for obesity: A Meta-analysis of randomized controlled trials[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(6): 651-656.

参考文献

[1] 王平芳,杨雅,廖二元,等.西布曲明对肥胖伴糖脂代谢异常的治疗作用[J].中国临床药理学与治疗学,2002,7(3):224-226.
[2] 王绘,陈斌.西布曲明对不同肥胖者的减重作用[J].中国临床药理学与治疗学,2002,7 (4):327-330.
[3] Hanif MW, Kumar S. Pharmacological management of obesity [J].Expert Opin Pharmacother, 2002, 3 (12):1711-1718.
[4] Ressner S, Sjestrem L, Noack R, et al. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. Eur Opean Orlistat Obesity Study Gruop [J].Obes Res, 2000, 8 (1):49-61.
[5] Bollinger A. Orlistat in the treatment of obesity[J]. Expert Opin Pharmacother, 2000,1(4):841-847.
[6] NIH conference. Gastrointestinal surgery for severe obesity. Consensus Development Conference Panel [J]. Ann Intern Med, 1991, 115(12):956-961.
[7] Derosa G, Cicero AF, Murdolo G, et al. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients[J]. Diabetes Obes Metab, 2005, 7(1):47-55.
[8] Kaya A, Aydin N, Topsever P, et al. Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients [J]. Biomed Pharmacother, 2004, 58(10):582-587.
[9] Gokcel A, Gumurdulu Y, Karakose H, et al. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity [J]. Diabetes Obes Metab, 2002, 4(1):49-55.
[10] Sari R, Balci MK, Cakir M, et al. Comparison of efficacy of sibutramine or orlistat versus their combination in obese women [J]. Endocr Res, 2004, 30(2):159-167.
[11] Gursoy A, Erdogan MF, Cin MO, et al. Comparison of orlistat and sibutramine in an obesity management program: efficacy, compliance, and weight regain after noncompliance [J]. Eat Weight Disord, 2007, 11(4):127-132.

[1]	刘雅琦，陆梦洁，刘玉秀，陈羽，袁阳丹，周憧憧，刘曼. 倍比分组双盲随机对照试验的盲态分析[J]. 中国临床药理学与治疗学, 2019, 24(10): 1155-1160.
[2]	伍长娟，汤天生. 振源胶囊辅助治疗慢性心力衰竭疗效及安全性的Meta分析[J]. 中国临床药理学与治疗学, 2017, 22(3): 299-304.
[3]	杭永付，卢国元，沈蕾，高杰，乔青，李明，沙文刚，周玲，丁肖梁，谢诚. 来氟米特治疗IgA肾病安全性和有效性的Meta分析[J]. 中国临床药理学与治疗学, 2017, 22(1): 60-67.
[4]	伍艳, 吴翠芳, 汪江林. 利西拉来治疗2型糖尿病的有效性及安全性的Meta分析[J]. 中国临床药理学与治疗学, 2015, 20(2): 167-174.
[5]	樊茂蓉, 王冰, 高金柱, 樊长征, 张琼. 三拗片治疗急性支气管炎(风寒袭肺证)的临床研究[J]. 中国临床药理学与治疗学, 2014, 19(1): 44-47.
[6]	张琼, 苗青, 张燕萍, 樊茂蓉. 参果老年感冒颗粒治疗老年体虚感冒(气虚肺热证)的多中心、随机、双盲、对照试验[J]. 中国临床药理学与治疗学, 2013, 18(9): 1019-1024.
[7]	王华富, 丁汀, 商振球, 桂志红, 林慧萍, 孙慧伶. 奥曲肽对肝硬化食管胃底静脉曲张破裂出血维持治疗的Meta分析[J]. 中国临床药理学与治疗学, 2012, 17(7): 768-772.
[8]	吴家利, 刘文华, 尹平. 米卡芬净治疗真菌感染的疗效与安全性的Meta分析[J]. 中国临床药理学与治疗学, 2012, 17(1): 64-68.
[9]	高小梅, 王柏松, 宋艳艳, 祁红, 荣征星, 王昊. 针刺治疗偏头痛的系统评价和Meta分析[J]. 中国临床药理学与治疗学, 2011, 16(5): 530-537.
[10]	刘玉秀, 成琪, 刘丽霞. 2010版CONSORT声明:平行组随机试验报告的新指南[J]. 中国临床药理学与治疗学, 2010, 15(10): 1189-1194.
[11]	李延鸿, 朱怀军. 紫杉醇治疗中国人群非小细胞肺癌的系统评价[J]. 中国临床药理学与治疗学, 2010, 15(1): 74-81.
[12]	李延鸿, 朱怀军. 参松养心胶囊治疗室性早搏随机对照试验的系统评价[J]. 中国临床药理学与治疗学, 2009, 14(8): 915-923.
[13]	石庆平, 丁峰, 朱锦秀, 程鹏, 许善初, 刘雁. 脉络宁注射液治疗脑梗死的系统评价[J]. 中国临床药理学与治疗学, 2009, 14(6): 650-654.
[14]	郑文艳, 曹于平. 托拉塞米注射剂治疗慢性充血性心衰伴水肿临床随机对照研究[J]. 中国临床药理学与治疗学, 2008, 13(6): 699-703.
[15]	崔明霞, 王磊, 张宝来, 路莉, 王莉, 郑荣梁, 吴勇杰. 糖尿病性肥胖大鼠模型的建立及西布曲明对其治疗作用的研究[J]. 中国临床药理学与治疗学, 2008, 13(12): 1325-1329.